ChartRow logo
Share this page

INCY — Incyte Corp. price, chart and key statistics

Technical analysis2
Overlay lines0
Addendum charts0
What would $1,000 invested in INCY be worth today? →
INCY returns: By year · By month · By week · Trailing

Key stats#

Price data

Price
$122.83
YTD price return
+24.36%
YTD total return
+24.36%
Market cap
25B
Enterprise value
21.8B
Shares outstanding
203.8M
52W low
$89.25
52W high
$132.60
From 52W high
-7.37%
From 52W low
+37.62%
52W range
77%$89.25–$133
Beta
0.76

Volume

Rel volume
1.85×
30D volume
1.9M
30D $ vol
223M

Insider trading

Insider net 1W
none
Insider net 1M
−$298K
Insider net 3M
−$5.7M
Insider net 1Y
−$28.6M

Form 4 transactions by trade date, as filed; latest on file 2026-10-15.

Fundamentals

Sales (ttm)
6B
Sales/share
$29.49
EPS (ttm)
$1.96
FCF (ttm)
684.9M
FCF/share
$3.36
Book value/share
$27.68
Net margin
6.71%
ROE
7.15%
ROA
5.54%
Current ratio
3.84

Growth (CAGR, ttm) · 10Y

Sales
+24.90%+18.53%+11.21%+19.37%
Net income
-66.08%-1.72%-5.48%+10.36%
FCF
-42.81%+5.64%+0.36%+14.41%
Shares
+3.83%-3.11%-1.59%+0.79%

Per-share growth (CAGR, ttm) · 10Y

EPS
-66.81%+1.35%-4.04%+9.66%
Sales/share
+20.30%+22.34%+13.01%+18.44%
FCF/share
-44.92%+9.03%+1.98%+13.55%
Book value/share
+16.86%+7.95%+14.20%+30.29%
Price
+19.36%+30.79%+12.72%+3.96%
Total return
+19.36%+30.79%+12.72%+3.96%

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)
62.6×
P/OI (ttm)
40.0×
Fwd P/E
14.0×
P/S (ttm)
4.2×
P/B (mrq)
4.4×
P/FCF (ttm)
36.6×
EV/EBITDA (fy)
30.1×
EV/Sales (ttm)
3.6×
FCF yield (ttm)
2.74%
Buyback yield (realized, 1y)
-3.83%
Shareholder yield (realized, 1y)
-3.83%
Buyback yield (cash, ttm)
0.00%
Shareholder yield (cash, ttm)
0.00%

Vs own 10Y history

P/E
72nd
P/OI
64th
P/S
35th
P/B
46th
P/FCF
69th

Bar = where today’s multiple sits in INCY’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).

Performance · price returntotal return · as of 2026-11-04#

1D
+4.46%
5D
+5.10%
1M
+6.53%
3M
+1.85%
YTD
+24.36%
1Y
+19.35%
5Y
+82.00%
1D
+4.46%
5D
+5.10%
1M
+6.53%
3M
+1.85%
YTD
+24.36%
1Y
+19.35%
5Y
+82.00%

Fundamentals#

Revenue

5Y CAGR +14.0%10Y CAGR +21.2%YoY +14.0%
$6B TTM$1.6B Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q3 '16Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Operating income

5Y n/m10Y CAGR +40.5%YoY n/m
$626.5M TTM−$708.4M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q3 '16Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

EPS (diluted)

5Y n/m10Y CAGR +71.0%YoY n/m
$1.96 TTM−$3.86 Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q3 '16Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Free cash flow

5Y n/m10Y CAGR +35.8%YoY n/m
$684.9M TTM−$691M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM

TTM: operating cash flow $745M, capex −$60.1M

Q3 '16Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Q3 2026: operating cash flow −$675.3M, capex −$15.6M

Shares (diluted)

5Y −8.0%10Y +7.2%YoY +0.9%
205.7M TTM203.2M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q3 '16Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Net income

5Y n/m10Y CAGR +69.6%YoY n/m
$403.4M TTM−$784.8M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q3 '16Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Full INCY financials →

About Incyte#

Incyte Corp. is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. The company’s current portfolio centers on hematology, oncology, and inflammation and autoimmunity, with products and programs aimed at treating cancers, blood disorders, and immune-mediated conditions. Incyte Corp. develops both small-molecule medicines and biologics, and its marketed therapies support patients with a range of specialty disease areas, including dermatology and rare hematologic disorders. The company also maintains a pipeline of clinical-stage candidates across its core therapeutic franchises, reflecting its role as a research-driven developer of targeted treatments. Headquartered in Wilmington, Delaware, Incyte Corp. serves healthcare markets in the United States and internationally through its commercial and development activities.

Wilmington, DE·2,844 employees·Biotechnology·incyte.com·As of Oct 28, 2026

Recent filings#

All filings and insider trades →

ETFs holding INCY#

33 of the 193 ETFs ChartRow carries live hold INCY. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).

FundNameFiled weight
IBBiShares Biotechnology ETF1.7%
XBISPDR S&P Biotech ETF1.0%
VBKVanguard Small-Cap Growth ETF0.5%
COWZPacer US Cash Cows 100 ETF0.5%
XLVHealth Care Select Sector SPDR Fund0.3%
VHTVanguard Health Care ETF0.3%
VBVanguard Small-Cap ETF0.2%
RSPInvesco S&P 500 Equal Weight ETF0.2%
TickerName1M1D
LLYEli Lilly and Company+24.07%+0.61%
JNJJohnson & Johnson+7.92%+3.81%
ABBVAbbVie Inc.+12.18%+3.09%
MRKMerck & Co. Inc.+4.20%+3.93%
UNHUnitedHealth Group Incorporated Common Stock (DE)+10.08%+1.22%
NVSNovartis AG+17.01%+3.59%
TMOThermo Fisher Scientific Inc.+7.84%+1.12%
AMGNAmgen Inc.+18.69%+3.71%